Beese Fulmer Investment Management Inc. Cuts Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Beese Fulmer Investment Management Inc. decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 3.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 135,737 shares of the medical research company’s stock after selling 4,288 shares during the quarter. Beese Fulmer Investment Management Inc.’s holdings in Edwards Lifesciences were worth $10,049,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Czech National Bank raised its stake in Edwards Lifesciences by 6.9% in the 3rd quarter. Czech National Bank now owns 122,715 shares of the medical research company’s stock worth $8,098,000 after acquiring an additional 7,883 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Edwards Lifesciences by 21.6% in the third quarter. GAMMA Investing LLC now owns 4,105 shares of the medical research company’s stock worth $271,000 after purchasing an additional 730 shares during the last quarter. Alpha Financial Partners LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth about $693,000. BSN CAPITAL PARTNERS Ltd purchased a new stake in Edwards Lifesciences in the third quarter valued at approximately $11,746,000. Finally, Tobam increased its holdings in Edwards Lifesciences by 2,756.8% in the 3rd quarter. Tobam now owns 75,647 shares of the medical research company’s stock worth $4,992,000 after buying an additional 72,999 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Barclays upped their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a report on Monday, December 2nd. Robert W. Baird decreased their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Royal Bank of Canada raised their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday, December 5th. Finally, Wolfe Research lowered Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a research note on Thursday, January 16th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $79.19.

Edwards Lifesciences Stock Down 1.6 %

EW opened at $70.96 on Friday. The business’s 50-day simple moving average is $72.49 and its 200-day simple moving average is $69.54. The stock has a market capitalization of $41.85 billion, a P/E ratio of 10.24, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,000 shares of company stock valued at $547,430. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.